Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China

Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study

(2016) Robert Provenzano et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD

(2016) R. Provenzano et al.   Clinical Journal of the American Society of Nephrology

Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease

(2016) Ya Li et al.   MEDICINE

Understanding the Recent Increase in Ferritin Levels in United States Dialysis Patients: Potential Impact of Changes in Intravenous Iron and Erythropoiesis-Stimulating Agent Dosing

(2015) A. Karaboyas et al.   Clinical Journal of the American Society of Nephrology

Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients

(2015) A. Besarab et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality

(2015) George R. Bailie et al.   KIDNEY INTERNATIONAL

Anaemia in kidney disease: harnessing hypoxia responses for therapy

(2015) Mark J. Koury et al.   Nature Reviews Nephrology

Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients

(2015) Anatole Besarab et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Mechanisms of Anemia in CKD

(2012) J. L. Babitt et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Prevalence of chronic kidney disease in China: a cross-sectional survey

(2012) Luxia Zhang et al.   LANCET

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

(2011) Colin Baigent et al.   LANCET

Role of the hypoxia inducible factors HIF in iron metabolism

(2010) Carole Peyssonnaux et al.   CELL CYCLE

Transfusion Burden among Patients with Chronic Kidney Disease and Anemia

(2010) E. V. Lawler et al.   Clinical Journal of the American Society of Nephrology

Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD

(2010) W. M. Bernhardt et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

What Is So Bad About a Hemoglobin Level of 12 to 13 g/dL for Chronic Kidney Disease Patients Anyway?

(2009) Anatole Besarab et al.   ADVANCES IN CHRONIC KIDNEY DISEASE

Baseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)

(2009) Marc A. Pfeffer et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Clinical characteristics and outcomes of rural patients with ESRD in Guangxi, China: one dialysis center experience

(2009) Wenxin Zhang et al.   INTERNATIONAL UROLOGY AND NEPHROLOGY

Community-based study on CKD subjects and the associated risk factors

(2009) Nan Chen et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes

(2008) Lynda A. Szczech et al.   KIDNEY INTERNATIONAL

Anemia and Cardiovascular Risk in the Patient with Kidney Disease

(2008) Steven Fishbane   Heart Failure Clinics

The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes

(2007) A. Mohanram et al.   KIDNEY INTERNATIONAL